Interstitial lung disease unmasked as myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis following acute kidney injury
DOI:
https://doi.org/10.18203/2320-6012.ijrms20264214Keywords:
ANCA-associated vasculitis, Myeloperoxidase, Interstitial lung disease, Crescentic glomerulonephritis, Acute kidney injury, Microscopic polyangiitisAbstract
Small-vessel vasculitis driven by antineutrophil cytoplasmic antibodies (ANCA) is a severe, systemic autoimmune condition whose clinical behavior can be notoriously unpredictable. When the offending antibody targets myeloperoxidase (MPO), the disease most commonly manifests as microscopic polyangiitis (MPA), a necrotizing vasculitis that, unlike its granulomatous counterparts, destroys vessel walls without forming granulomas. We report a 49-year-old woman who had been living with what appeared to be idiopathic interstitial lung disease (ILD) for a full year before presenting to our emergency department in florid acute respiratory failure. She required emergent intubation for severe metabolic acidosis and, within 48 hours of admission, her kidneys, previously unaffected, collapsed into acute kidney injury (AKI) necessitating hemodialysis (HD). Serological testing came back strongly positive for MPO-ANCA, and renal biopsy showed crescentic glomerulonephritis (GN) in a pauci-immune pattern, confirming the diagnosis. We initiated plasmapheresis, high-dose pulse methylprednisolone, and cyclophosphamide, with rituximab planned as sequential therapy. Despite a brief biochemical response at three weeks, her clinical trajectory proved irreversible and she died. A high index of suspicion for underlying vasculitis is essential in any patient with established pulmonary fibrosis who develops sudden, unexplained renal deterioration.
Metrics
References
Salvati L, Palterer B, Lazzeri E, Vivarelli E, Amendola M, Allinovi M, et al. Presentation and progression of MPO-ANCA interstitial lung disease. J Transl Autoimmun. 2024;8:100235. DOI: https://doi.org/10.1016/j.jtauto.2024.100235
Singh A, Everest S, Nguyen L, Kasari M. ANCA-associated vasculitis in a patient presenting with rapid progressive glomerulonephritis. Cureus. 2021;13(12):e20227. DOI: https://doi.org/10.7759/cureus.20227
Yamakawa H, Toyoda Y, Baba T, Kishaba T, Fukuda T, Takemura T, et al. Anti-inflammatory and/or anti-fibrotic treatment of MPO-ANCA-positive interstitial lung disease: a short review. J Clin Med. 2022;11(13):3835. DOI: https://doi.org/10.3390/jcm11133835
Kim MJ, Lee D, Choe J, Song JW. Long-term clinical course and outcomes of patients with microscopic polyangiitis-associated interstitial lung disease. Front Pharmacol. 2023;14:1064307. DOI: https://doi.org/10.3389/fphar.2023.1064307
Zhao W, Dai H, Liu Y, Zhu M, Bao N, Ban C, et al. Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis. Clin Respir J. 2019;13(7):460–6. DOI: https://doi.org/10.1111/crj.13032
Song Q, Liu Y, Wu T, Zhang Y, Yan Y, Xiao S. Clinical features, radiological findings and prognosis of microscopic polyangiitis with interstitial lung disease: a retrospective matched control study. BMC Pulm Med. 2024;24(1):605. DOI: https://doi.org/10.1186/s12890-024-03423-w
Zhou P, Ma J, Wang G. Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: a systematic literature review and meta-analysis. Chron Respir Dis. 2021;18:1479973121994562. DOI: https://doi.org/10.1177/1479973121994562
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32. DOI: https://doi.org/10.1056/NEJMoa0909905
Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20. DOI: https://doi.org/10.1056/NEJMoa0909169
Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366–83. DOI: https://doi.org/10.1002/art.41773
Walsh M, Merkel PA, Peh CA, Szpirt WM, Puechal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–31. DOI: https://doi.org/10.1056/NEJMoa1803537
Odler B, Riedl R, Geetha D, Szpirt WM, Hawley C, Uchida L, et al. The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial. Kidney Int. 2025;107(3):558–67. DOI: https://doi.org/10.1016/j.kint.2024.11.029
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Nisha B. Jana, Bahlah A. Surka, Yatri S. Patel

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.